What type of study is this?

September 10, 2025VaccinesOpen Access

ImmuniT Platform for Improved Neoantigen Prediction in Lung Cancer

View Full Paper

Ask AI

Bookmark

Authors

Observational analysis shows expanded neoantigen discovery in lung cancer patients, highlighting potential in immunotherapy.

ImmuniT identified a broader spectrum of neoantigens compared to conventional approaches, leading to stronger T cell activation.
The platform validated candidate neoantigens in five patient samples, confirming tumor-specific T cell responses in both compartments.
Development included co-culturing autologous T cells with treated cancer cells to enhance tumor-reactive populations.
ImmuniT may improve personalized immunotherapy strategies for patients with limited responses to existing treatments.

Hachey et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark